Novartis to invest $100m in biopharmaceuticals production in Slovenia
Ljubljana, 12 September - Swiss pharma giant Novartis, of which Slovenian pharma company Lek is a part, plans to invest 300 million US dollars in early technical development capabilities for next-generation biotherapeutics, of which 110 million dollars at one of its Slovenian locations in Mengeš.
Mengeš
Drug production machinery at Lek's Mengeš location.
Photo: Daniel Novakovič/STA
The rest of this news item is available to subscribers.
The news item consists of 981 characters (without spaces) or 168 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.